CA-CONVIVA
9.9.2022 12:21:36 CEST | Business Wire | Press release
Conviva, the global streaming analytics platform, released today the results of its quarterly State of Streaming Report, which shows continued growth in the global streaming market, including gains of (14%) in the second quarter of 2022 as compared to Q2 2021. Asia and Latin America saw the most growth — 90% and 70%, respectively — while North America, the most mature streaming market in the world, also grew 5% year over year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005099/en/
Conviva's State of Streaming Report Q2 2022 (Graphic: Business Wire)
As the global streaming industry matures, streaming success is getting more complicated. Device fragmentation is growing, and viewers’ quality expectations continue rising in concert with an ad-supported streaming world. Streaming publishers are challenged to deliver a consistent and positive experience. Whether in Africa using an Android phone or in Texas on a Smart TV – viewers expect a quality picture, instant access to content and zero glitches.
“The race is on to see which publishers will meet these expectations, including providing the best experience when it’s most important,” said Keith Zubchevich, President and CEO, Conviva. “Those who do will quickly eclipse the competition. Most importantly, those who make it a priority to obtain real-time actionable insights about their customers’ (real-world experiences) will undoubtedly separate the leaders from the pack,” added Zubchevich.
Key Findings
Bitrates are Rising
Conviva found bitrate rose globally in Q2 2022 across all screen types and devices, but often at the expense of other quality metrics. For example, Smart TVs saw the largest increase in bitrate of all screen types, up 15.1% year over year. However, to provide this more high-definition experience, Smart TVs saw noticeable increases in video start failures, video start time and buffering. Conversely, PlayStation and Roku were the only big screen devices to both decrease video start times (down 10.7% and 12% respectively) and increase bitrate (up 4.6% and 12.9% respectively).
Big Screens – and Roku – Remain on Top
Roku continued to hold the top spot among big screen devices (big screens include connected TVs, Smart TVs and gaming consoles), holding nearly steady at 30.5% of viewing time, down less than one percent as compared to Q2 2021 with Amazon Fire TV coming in second with 16% of big screen viewing time. Samsung TV (13.7%), Android TV (7.8%) and LG TV (7.3%) rounded out the top five devices for big screen viewing time. Chromecast, Xbox and PlayStation all saw a decrease in share as compared to the previous year.
Android vs iPhone Streaming Showdown
To date, the iPhone has been the primary device for mobile streaming, especially in North America. In Q2 2022 the gap closed, with iPhone and Android phones capturing nearly identical global market share, 35.8% vs 33.2% respectively. In addition, Android phones outpaced the iPhone by 10% in YoY growth in streaming viewing hours. In Apple’s favor is its quality — as the iPhone currently beats Android phones in every quality category. As streaming publishers expand into newer, less mature streaming markets outside of North America, optimizing the streaming experience for the android mobile device market will be of increasing importance.
Methodology
Conviva’s State of Streaming series is the largest cross-platform comparison of streaming data measuring ongoing, real-time, sessionized streaming data at Internet-scale.
Data analyzed for the Q2 2022 State of Streaming report was primarily collected from Conviva’s unique proprietary sensor technology. Currently embedded in 3.3 billion streaming video applications, it measures more than 500 million unique viewers watching 180 billion streams per year and nearly 2 trillion real-time transactions per day across more than 180 countries. The Internet-scale census-measurement is deployed from a full-stack censor that is not sampled, but validated, cleaned, enriched, standardized and sessionized. Continuous, real-time monitoring sessionizes streaming events, state timelines and meta data into viewer-led sessions. This more accurately reflects viewers’ real-world experiences.
The social media data, collected from the Streaming Publishers leaderboard list within Conviva Social Insights, consists of data from 100 accounts, over 7,500 million posts, and over 30 million engagements across Facebook, Instagram, Twitter, TikTok and YouTube between Q2 2021 and Q2 2022.
Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth.
Get a copy of Conviva’s Q2 State of Streaming Report
About Conviva
Conviva is the only global streaming analytics platform for big data that collects, standardizes, and puts trillions of streaming data points in context, in real time. With Conviva, streaming businesses can understand real-world human experiences within seconds of observation and take action to grow their business ahead of the competition.
The Conviva platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. It includes first-of-its kind-innovations like time-state analytics and AI automated data modeling. Using a single full stack sensor at the source, coupled with a single big data pipeline, Conviva’s 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock incredible opportunity with streaming analytics. To learn more, visit www.conviva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
